Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06970847 · ClinicalTrials.gov registry record · Phase 3
64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer
A Phase 3 study of Prostate Cancer and Prostate Cancer Recurrent, sponsored by Clarity Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 220
- Enrollment target
- 20
- Study locations
NCT06970847: Recruiting Phase 3 study of Prostate Cancer and Prostate Cancer Recurrent, sponsored by Clarity Pharmaceuticals.
NCT06970847 is a Phase 3 study of Prostate Cancer and Prostate Cancer Recurrent that is actively recruiting participants, run by Clarity Pharmaceuticals. The registered enrollment target is 220 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (64% lower). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06970847, a Phase 3 study of Prostate Cancer and Prostate Cancer Recurrent, is actively recruiting participants, sponsored by Clarity Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 220 participants
- Enrollment target
- 20
- Study locations
Study Summary
The aim for this study is to investigate the ability of 64Cu-SAR-bisPSMA PET/CT to detect recurrence of prostate cancer
Primary Outcome
Co-primary endpoints of participant-level CDR and region level PPV assessed independently for Day 1 and Day 2: * Participant-level CDR, defined as the proportion of TP participants scan out of all participants * Region-level PPV, defined as the proportion of TP regions out of all positive regions.
Conditions Studied
Interventions
- DRUG 64Cu-SAR-bisPSMA
Study Locations (20)
California
- UC Irvine - Irvine
- Comprehensive Urology Medical Group - Los Angeles
- Alarcon Urology Center - Montebello
Florida
- University of Florida Health- Jacksonville - Jacksonville
- Biogenix Molecular - Miami
Arizona
- East Valley Urology Center of Arizona - Mesa
Arkansas
- Arkansas Urology Research Center - Little Rock
Illinois
- Endeavor Health - Evanston
Indiana
- Indiana University Health-IU Simon Cancer Center - Indianapolis
Kansas
- Wichita Urology Group - Wichita
Louisiana
- XCancer Research Network / LCMC Health EJGH - Metairie
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2025-05-16 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 3 |
What NCT06970847 shows while recruiting
NCT06970847 is an interventional study that assigns participants to a tested intervention. The registered 220 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (64% lower).
The record links to 6 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which 64Cu-SAR-bisPSMA is the first listed.
NCT06970847 names 20 study sites across 17 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT06970847 about?
NCT06970847 is a clinical study titled "64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer". The aim for this study is to investigate the ability of 64Cu-SAR-bisPSMA PET/CT to detect recurrence of prostate cancer
What is the current status of trial NCT06970847?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 220 participants. The study started on 2025-05-16. Estimated completion is 2026-12-31.
What conditions does trial NCT06970847 study?
This clinical trial studies the following conditions: Prostate Cancer, Prostate Cancer Recurrent, Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer Patients With Detectable PSA Following Prostatectomy, Prostate Cancer Patients Who Have Brachytherapy Seed Implant.
What interventions are being tested in trial NCT06970847?
The interventions under investigation include: 64Cu-SAR-bisPSMA (DRUG).
Who is sponsoring clinical trial NCT06970847?
This trial is sponsored by Clarity Pharmaceuticals, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06970847 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06970847's enrollment target sits among peer trials
220 208th of 735 higher than 526 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
RECRUITING · Phase 3
-
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
RECRUITING · Phase 3
-
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
RECRUITING · Phase 3
-
Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)
RECRUITING · Phase 3
-
SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)
RECRUITING · Phase 3
-
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00920972 · 220 participants · Phase 1
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
- NCT01851642 · 220 participants
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
- NCT02582021 · 220 participants
WISE CVD - Continuation (WISE HFpEF)
- NCT04067830 · 220 participants · Phase 2
Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI